the market?
Amgen, Inc.
NASDAQ: AMGN
105.62
1.09
(1.04%)
Extended Hours:
$105.62
$0.00
(0.00%)
| Today's Open | $103.10 |
|---|---|
| Previous Close | $104.53 |
| Daily Range | $103.00 - $106.33 |
| 52-Week Range | $67.61 - $114.95 |
| Market Cap | $79.2B |
| P/E Ratio | 17.66 |
| Dividend (Yield) | $1.88 (1.8%) |
| Ex-Dividend Date Dividend Pay Date |
05/14/13 06/07/13 |
| Volume | 3,128,014 |
| Average Daily Volume | 4,006,106 |
| Current FY EPS | $7.19 |
How do you think AMGN
will perform against the market?
Top AMGN Bull/Bear Pitches
FreeMortal (< 20)
Submitted
December 23, 2009
Steadily growing earnings. Excellent margins and ROE. PE is fair, but it looks like this will drop; not because the price will drop, but because the earnings are poised to rise.
News & Commentary
Can Financial Innovation Unlock a Cure for Cancer?
Andrew W. Lo from the MIT Sloan School of Management has a rather Foolish idea for solving the world's biggest problems.Will Amgen's Novel Drug Revolutionize Cancer Treatment?
A new first-of-its-kind immunotherapy trains the immune system to target cancer cells. Can it revolutionize cancer treatment for good?Sanofi and Regeneron's Latest Partnership
Late-stage clinical trials begin for this duo's experimental rheumatoid arthritis drug.Don't Get Too Excited About This Cancer Drug Yet
Biotech giant Amgen recently announced positive phase 3 results for its cancer drug Vectibix. While it should increase sales from current levels, it lacks the "wow!" factor investors may be looking for.Sector
Healthcare
Industry
Drugs
Amgen, Inc. (AMGN) Description
A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Website: http://www.amgen.com/
CEO Rating by Glassdoor
More details for Amgen Jobs
Amgen reviews from employees
